616 related articles for article (PubMed ID: 30041669)
1. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.
Mukherjee S; Fried A; Hussaini R; White R; Baidoo J; Yalamanchi S; Banerjee P
J Exp Clin Cancer Res; 2018 Jul; 37(1):168. PubMed ID: 30041669
[TBL] [Abstract][Full Text] [Related]
2. Liposomal TriCurin, A Synergistic Combination of Curcumin, Epicatechin Gallate and Resveratrol, Repolarizes Tumor-Associated Microglia/Macrophages, and Eliminates Glioblastoma (GBM) and GBM Stem Cells.
Mukherjee S; Baidoo JNE; Sampat S; Mancuso A; David L; Cohen LS; Zhou S; Banerjee P
Molecules; 2018 Jan; 23(1):. PubMed ID: 29346317
[TBL] [Abstract][Full Text] [Related]
3. Curcumin changes the polarity of tumor-associated microglia and eliminates glioblastoma.
Mukherjee S; Baidoo J; Fried A; Atwi D; Dolai S; Boockvar J; Symons M; Ruggieri R; Raja K; Banerjee P
Int J Cancer; 2016 Dec; 139(12):2838-2849. PubMed ID: 27543754
[TBL] [Abstract][Full Text] [Related]
4. TriCurin, a synergistic formulation of curcumin, resveratrol, and epicatechin gallate, repolarizes tumor-associated macrophages and triggers an immune response to cause suppression of HPV+ tumors.
Mukherjee S; Hussaini R; White R; Atwi D; Fried A; Sampat S; Piao L; Pan Q; Banerjee P
Cancer Immunol Immunother; 2018 May; 67(5):761-774. PubMed ID: 29453519
[TBL] [Abstract][Full Text] [Related]
5. A New Perspective on Cancer Therapy: Changing the Treaded Path?
Baidoo JNE; Mukherjee S; Kashfi K; Banerjee P
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575998
[TBL] [Abstract][Full Text] [Related]
6. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
7. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
[TBL] [Abstract][Full Text] [Related]
9. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.
Avril T; Vauleon E; Hamlat A; Saikali S; Etcheverry A; Delmas C; Diabira S; Mosser J; Quillien V
Brain Pathol; 2012 Mar; 22(2):159-74. PubMed ID: 21790828
[TBL] [Abstract][Full Text] [Related]
10. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma.
Hutter G; Theruvath J; Graef CM; Zhang M; Schoen MK; Manz EM; Bennett ML; Olson A; Azad TD; Sinha R; Chan C; Assad Kahn S; Gholamin S; Wilson C; Grant G; He J; Weissman IL; Mitra SS; Cheshier SH
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):997-1006. PubMed ID: 30602457
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
13. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment.
Dumas AA; Pomella N; Rosser G; Guglielmi L; Vinel C; Millner TO; Rees J; Aley N; Sheer D; Wei J; Marisetty A; Heimberger AB; Bowman RL; Brandner S; Joyce JA; Marino S
EMBO J; 2020 Aug; 39(15):e103790. PubMed ID: 32567735
[TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
Front Immunol; 2021; 12():637053. PubMed ID: 34108959
[TBL] [Abstract][Full Text] [Related]
15. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1.
Szulzewsky F; Pelz A; Feng X; Synowitz M; Markovic D; Langmann T; Holtman IR; Wang X; Eggen BJ; Boddeke HW; Hambardzumyan D; Wolf SA; Kettenmann H
PLoS One; 2015; 10(2):e0116644. PubMed ID: 25658639
[TBL] [Abstract][Full Text] [Related]
16. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
17. Interactions between tumor-associated macrophages and tumor cells in glioblastoma: unraveling promising targeted therapies.
Morisse MC; Jouannet S; Dominguez-Villar M; Sanson M; Idbaih A
Expert Rev Neurother; 2018 Sep; 18(9):729-737. PubMed ID: 30099909
[TBL] [Abstract][Full Text] [Related]
18. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis.
Feng X; Szulzewsky F; Yerevanian A; Chen Z; Heinzmann D; Rasmussen RD; Alvarez-Garcia V; Kim Y; Wang B; Tamagno I; Zhou H; Li X; Kettenmann H; Ransohoff RM; Hambardzumyan D
Oncotarget; 2015 Jun; 6(17):15077-94. PubMed ID: 25987130
[TBL] [Abstract][Full Text] [Related]
19. EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment.
Yin Y; Qiu S; Li X; Huang B; Xu Y; Peng Y
J Neuroinflammation; 2017 Nov; 14(1):220. PubMed ID: 29132376
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
